Herpes Zoster Clinical Trials

221 clinical trials for Herpes Zoster across international registries, including 31 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population — RECRUITING · PHASE1
• Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine — RECRUITING
• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland — RECRUITING · PHASE4
• Shingrix in Renal Transplant Recipients — RECRUITING · PHASE3
• The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster — RECRUITING · NA
• A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant — RECRUITING · PHASE1
• Erector Spinae Plane Block Versus Transcutaneous Radiofrequency in Postherpetic Neuralgia — RECRUITING
• Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine — RECRUITING · PHASE1
• Electroacupuncture Regulation of Immune Cells in Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Loxoprofen Sodium Patch in Patients With Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Tulodesvenlafaxine in Patients With Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Flurbiprofen Patch in Patients With Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster — RECRUITING · NA
• The Analgesic Efficacy and Safety of Crisugabalin in Patients With Herpes Zoster — RECRUITING · NA
• A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals — RECRUITING · PHASE1
• Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster — RECRUITING · PHASE4
• A Study That Collects Participant Data and Biospecimens to Analyze Pathogenic Exosomes That Mediate Increased Vascular Dementia Risk in Individuals With Herpes Zoster. — RECRUITING
• Clinical Study on the Treatment of Herpes Zoster Pain With Dexmedetomidine Combined With Long-term High Voltage — RECRUITING · PHASE2
• Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia — RECRUITING · NA
• Safety and Immunogenicity of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older — RECRUITING · PHASE1
• Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above — RECRUITING · PHASE1
• Risk Factors of Anxiety and Depression in Patients With Herpes Zoster Neuralgia — RECRUITING
• A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine — RECRUITING · PHASE3
• A PHASE I/II, OBSERVER-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTI-COUNTRY STUDY TO EVALUATE REACTOGENICITY, SAFETY, IMMUNE RESPONSE, AND EFFICACY OF AN HSV-TARGETED IMMUNOTHERAPY IN HEALTHY PARTICIPANTS AGED 18-40 YEARS OR IN PARTICIPANTS AGED 18-60 YEARS WITH RECURRENT GENITAL HERPES — RECRUITING · PHASE1
• A PHASE IIIB, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRE, LONG-TERM FOLLOW-UP STUDY (ZOE-LTFU) OF STUDIES 110390 AND 113077 (ZOSTER-005/022) TO ASSESS THE PROPHYLACTIC EFFICACY, SAFETY, AND IMMUNOGENICITY PERSISTENCE OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE AND ASSESSMENT OF 1 OR 2 ADDITIONAL DOSES ON A 0 OR 1, 2-MONTH SCHEDULE IN TWO SUBGROUPS OF OLDER ADULTS — RECRUITING · PHASE3
• A PHASE IIIB, NON-RANDOMIZED, OPEN-LABEL, MULTI-COUNTRY, MULTI-CENTRIC CROSS-VACCINATION STUDY TO EVALUATE THE SAFETY OF GSK BIOLOGICALS' HERPES ZOSTER SUBUNIT (HZ/SU) VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A TWO-DOSE SCHEDULE TO SUBJECTS WHO PREVIOUSLY RECEIVED PLACEBO IN ZOSTER-006 AND ZOSTER-022 STUDIES — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, DOUBLE BLIND MULTICENTER STUDY, TO EVALUATE CONSISTENCY, IMMUNOGENICITY, SAFETY AND REACTOGENICITY OF 3 LOTS OF GSK BIOLOGICALS' HERPES ZOSTER HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0 AND 2 MONTH SCHEDULE TO ADULTS >50 YEARS OF AGE — RECRUITING · PHASE3
• A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTRE CLINICAL TRIAL TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GSK BIOLOGICAL'S HERPES ZOSTER VACCINE GSK1437173A WHEN CO-ADMINISTERED WITH GSK BIOLOGICALS' QUADRIVALENT INFLUENZA VACCINE FLU-D-QIV (GSK2321138A) VERSUS SEPARATE ADMINISTRATION OF THE TWO VACCINES IN ADULTS AGED 50 YEARS AND OLDER — RECRUITING · PHASE3
• "A PHASE III, RANDOMISED, OBSERVER-BLIND, PLACEBO CONTROLLED, MULTICENTRE CLINICAL STUDY TO ASSESS THE IMMUNOGENICITY AND SAFETY OF GASK BIOLOGICALS HZ/SU CANDIDATE VACCINE WHEN ADMINISTERED INTRAMUSCULARLY ON A 0- AND 1- AND 2-MONTHS SCHEDULE TO ADULTS >18 YEARS OF AGE WITH RENAL TRANSPLANT." — RECRUITING · PHASE3
• A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age — COMPLETED · PHASE3
• A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (Inactivated) — COMPLETED · PHASE3
• VZV vaccination to prevent herpes zoster after transplantation — TERMINATED · PHASE4
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age — TERMINATED · PHASE1
• Clinical and Economic Impact of Herpes Zoster in Cancer Patients — COMPLETED
• Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over — ACTIVE_NOT_RECRUITING · PHASE1
• A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow- up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults. — TERMINATED · PHASE3
• Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain — NOT_YET_RECRUITING · NA
• The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept — COMPLETED · PHASE2
• A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants — COMPLETED · PHASE1
• Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above — NOT_YET_RECRUITING · PHASE2
• A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) — ACTIVE_NOT_RECRUITING · PHASE3
• A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above — TERMINATED · PHASE4
• Postherpetic Neuralgia After Herpes Zoster and Incident Dementia Risk — COMPLETED
• Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above — NOT_YET_RECRUITING · PHASE2
• A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older — ACTIVE_NOT_RECRUITING · PHASE2
• A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults — COMPLETED · PHASE3

Refine this search